| |
|
|
|
|
|
---=>>> HIGH RISING STOCK ALERT: (OTCQB) CBIS <<<=---
|
|
|
|
|
|
|
|
|
|
|
|
|
Welcome To Cannabis Science (OTCQB) CBIS
|
|
|
|
|
|
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives.
From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions. |
|
|
|
| (OTCQB) CBIS | Research & Development |
|
Our pursuit of knowledge is done creatively and diligently.
Our team of bright minds is always at work to undertake groundbreaking research, and use it to devise new, innovative, and exciting projects, such as medications that can save lives and change a patient’s way of life for the better, and expanding globally so that our positive influence reaches across borders.
|
|
|
|
| (OTCQB) CBIS | The Science of Cannabinoids |
|
Cannabinoids have an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. |
|
|
|
Cannabis Science (OTCQB) CBIS | Pipeline
|
|
See what Cannabis Science has in the works and their progress.
These programs will change the lives of many people of all ages, shapes, and sizes, with a variety of illnesses that cannabinoid-based medications can target.
These illnesses include cancer, HIV/AIDS, arthritis, chronic
pain, and a myriad of others. http://www.cannabisscience.com/ |
|
|
|
|
|
CBIS takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions.
Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements. |
|
|
|
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.
Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.
CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.
In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders."
The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety.
The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with partner company, ENDOCAN Corporation, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade development. |
|
|
|
(OTCQB) CBIS | Recent Developments-
Cannabis Science, Inc. (CBIS) to oversee Farmatech S.A research in Colombia.
May 15, 2014- New Colombia Resources, Inc. a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with Farmatech S.A., of Medellin, Colombia, for the research and development of topical cannabis based medicines to treat skin cancer and other ailments in Colombia.
Farmatech S.A. is a pharmaceutical laboratory that collaborates with private companies, universities, institutions and NGOs. Their mission is to manufacture medicines as well as cosmetic and veterinary products, both proprietary and by contract. New Colombia Resources is in discussions with Cannabis Science, Inc. (CBIS) to oversee research in Colombia once the protocols are established by Farmatech S.A.
Farmatech S.A. is GMP certified by INVIMA (National Institute of Food & Drug Vigilance) for the production of the following dosage formulations:
- Solids: Tablets with or without cover, hard gelatin capsules, lozenges, effervescent powders and granules.
- Semisolid: creams, gels and ointments; bulk manufacture of suppositories. Liquid solutions, emulsions, and suspensions.
- Non lactic antibiotics: Solid powder.
Farmatech S.A. has a manufacturing certificate from INVIMA for cosmetic liquids, creams and gels.
In association with Dr. Robert Melamede PhD, President of Cannabis Science Inc., New Colombia will work with Farmatech S.A. to develop products using formulations and processes specific to the ailment being treated. For more information on Farmatech S.A., visit www.farmatech.com.co.
"Dr. Bob Melamede and I first approached the owners of Farmatech S.A. to research cannabis based formulations in 2010, we all feel now is the right time to develop and market these products. We look forward to collaborating with Cannabis Science Inc, the Phoenix Tears Foundation, and Farmatech S.A. to bring new products to market," stated John Campo, President of New Colombia Resources, Inc. Full Press
|
|
|
|
|
Cannabis Science, Inc. (CBIS) | 6946 N Academy BlvdSuite B #254
Colorado Springs, CO 80918
|
|
|
|
|
Colorado Will Spend 10 Million Researching Marijuana's Medical Benefits
|
|
HUFFPosted: 05/21/2014 | Colorado Gov. John Hickenlooper (D) signed a bill Wednesday that will fund up to 10 million for research into the medical efficacy of marijuana.
"SB 155 invests the dollars collected from medical marijuana fees into a meaningful effort to study the therapeutic and medical benefits of the drug," state Rep. Crisanta Duran (D), a co-sponsor of the bill, told The Huffington Post. "Patients will benefit from this investment and Colorado will become a national leader in developing medical marijuana research."
The bill states the research will help Colorado determine which medical conditions should be added to the state's current list of eight ailments that make patients eligible for medical marijuana. It will also help physicians better understand the biochemical effects of prescribed marijuana, add to the growing base of knowledge built from several state-funded medical cannabis research programs about proper dosing and possibly allow the state to conduct clinical trials, the bill outlines.
"This bill is exciting because it gives researchers the opportunity to show why and how marijuana works, and to do research that the federal government refuses to conduct," Mike Elliott of Marijuana Industry Group told HuffPost.
The research will be funded through the state's 10 million medical marijuana program cash fund. Full Story
|
|
|
|
|
CBIS Appoints Dr. Roscoe M. Moore Jr., Retired US Assistant
Surgeon General for a Second Term
|
|
|
|
July 24, 2014 - Cannabis Science, Inc. (OTCQB) CBIS, a U.S. Company specializing in cannabis formulation-based drug development and related consulting is pleased to announce the appointment of Dr. Roscoe M. Moore, Jr., formerly the US Assistant Surgeon General, for a second term on the scientific advisory board and as a special Senior Advisor to the Company. Among other contributions, Dr. Moore will be leading the Cannabis Science initiative in Africa.
"We are delighted that Dr. Moore has agreed to continue to share his breadth of knowledge and experience with Cannabis Science executives and scientific advisors on epidemiology, government regulation, and international challenges in delivery of disease treatment", stated Dorothy H. Bray, Ph.D., Director, President and CEO, Cannabis Science, Inc.
About Roscoe M. Moore Jr., D.V.M., M.P.H., Ph.D., Senior Advisor to Cannabis Science and Senior Member of the Company's Scientific Advisory Board
Dr. Moore brings to the Company substantial experience and leadership through his government service that includes responsibilities as former Assistant United States Surgeon General and Rear Admiral in the USPHS.
Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA), along with the positions he held in the US Public Health Service (USPHS), and most recently, with the Office of the US Secretary of Health and Human Services (HHS).
Dr. Moore was named a Senior Fellow at the Potomac Institute in June 2003. He is currently the CEO and Vice Chairman of the Global Flu Consortium.
Dr. Moore was the top-ranking veterinarian in all of the Uniformed Services, and served as the Associate Director for Development Support and African Affairs for HHS. In this capacity, Dr. Moore was the principal liaison between HHS and ministries of health for 53 countries in Africa. He also held positions at the National Institutes of Health (NIH), the Centers for Disease Control (CDC).
Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; and an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. He has written or co-authored over 100 publications covering a broad range of public health issues.
For a full biography of Dr. Moore, please see http://phrockwood.com/adobePDFs/Biography.pdf.
|
|
|
|
|
---=>>> HIGH RISING STOCK ALERT: (OTCQB) CBIS <<<=---
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Disclaimer - Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing. You should not invest or trade in any penny stock unless are you are fully prepared, willing, able and expect to lose a hundred pct of your funds,including any profiled company or other company in any other manner mentioned or alluded to by carriage consulting as defined in any medium whatsoever. Consulting Group Compensation: three thousand dollars for a one day awareness on cbis from a third party.The service is provided as a guide to some available investments only, which must be tempered by the investment experience and independent decision making process of the subscriber. The accuracy of issuer documents and information that is submitted to and, its affiliated members and its management for inclusion on this site is principally the responsibility of the particular issuer and its management, its affiliated members and its management is neither responsible for, nor undertakes any steps to check, the accuracy of any information provided by featured companies to potential investors. You should confirm to your own satisfaction the veracity of any information prior to entering into any investment. |
|
|
